Merrion Fertility Clinic
Dublin, D02 NH93, Ireland
Location status: Recruiting
Location contact
David Crosby, MD
CONTACT
Louise E Glover, PhD
CONTACT
353 + 15567900
Louise Glover, PhD
CONTACT
Sarah Petch, MD
CONTACT
NCT Number: NCT06602687
Hyaluronic acid (HA) is a major component of the cumulus complex surrounding oocytes. Intracytoplasmic sperm injection (ICSI) involves injection of a selected sperm into the oocyte. Embryologists select sperm with normal morphology and progressive motility. Physiologic intracytoplasmic sperm injection (PICSI) involves sperm selection for ICSI based on hyaluronan binding. Mature sperm which bind to HA have greater genomic integrity and reduced levels of DNA fragmentation. Earlier observational studies demonstrated improved outcomes in assisted reproductive technologies (ART) including improved clinical pregnancy rates, decreased miscarriage rates and higher live birth rates. A large multicentre randomized trial, the HABSelect trial, which included over 2,500 couples, found that PICSI did not improve term (>37 weeks gestation) live birth rates compared to standard ICSI. However, mechanistic analysis of the data from the HABSelect trial showed a significant reduction in miscarriage rates, most notable in couples where the woman was aged over 37 years where a significant reduction in miscarriage rate was seen (40% with ICSI vs 15% with PICSI). A 2021 retrospective sibling oocyte study, including 45 cycles, compared fertilisation and embryo development and found higher fertilisation rate in PICSI cycles. No difference was observed in clinical pregnancy rates; miscarriage rates and live birth rates were not reported. We aim to prospectively study PICSI vs standard ICSI in sibling oocytes to investigate if PICSI improves embryological and ART outcomes, particularly fertilisation rate, embryo euploid status and miscarriage rate, where the female patient is aged over 35 years.
Interested in participating?
Request Info35 year and older
All sexes
Interventional
Not applicable
Dublin, D02 NH93, Ireland
Location status: Recruiting
David Crosby, MD
CONTACT
Louise E Glover, PhD
CONTACT
353 + 15567900
Louise Glover, PhD
CONTACT
Sarah Petch, MD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The PICSI® dish is a CE marked medical device containing dots of a HA hydrogel (Cooper Surgical).
Time frame: 4 weeks
Primary outcome is rate of euploid embryos per cycle after preimplantation genetic testing for aneuploidy (PGT-A)
Time frame: 24-48 hours
Defined as number of 2PNs per oocyte injected
Time frame: 5 and 6 days
Assessed on day 5 and day 6 according to Gardner grading system.
Time frame: 6-7 weeks
Defined as detection of urinary human chorionic gonadotropin (hCG) per embryo transfer cycles.
Time frame: 6-7 weeks
Defined as number of fetal heartbeats/ gestational sacs identified by ultrasonographic visualisation at 6-7 weeks gestation per cycles started, oocyte retrievals or embryo transfer cycles.
Time frame: up to 22 weeks
Defined as number of spontaneous losses of an intra-uterine pregnancy prior to 22 completed weeks of gestational age per embryo transfer cycles.
Time frame: 37-42 weeks
Defined as number of live births at ≥37 weeks gestation per embryo transfer cycles
Contact information is provided by the study sponsor or research team.
Merrion Fertility Clinic
Other
Sperm Hyaluronic Binding Selection (PICSI): Impact on Embryo Aneuploid Status in Assisted Human Reproduction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07036536
Aneuploidy, Chromosome Aberrations
Houston, Texas, United States
View Trial DetailsNCT06023472
Aneuploidy, Chromosomal Rearrangement
Hong Kong, China
View Trial DetailsNCT05488236
Aneuploidy, Chromosome Aberrations
Lisbon, Portugal
View Trial DetailsNCT06419127
Aneuploidy, Chromosome Aberrations
Fort Lauderdale, Florida, United States
View Trial Details